基于转录组学探讨清益护肺方调控HMGB1/TLR4/NF-κB通路治疗放射性肺炎的作用机制

Exploring the Mechanism of Qingyi Hufei Formula in Treating Radiation Pneumonitis by Regulating the HMGB1/TLR4/NF-κB Pathway Based on Transcriptomics

  • 摘要:
    目的 基于转录组学探讨清益护肺方(QHF)治疗放射性肺炎(RP)的作用机制。
    方法 将SPF小鼠随机分为空白对照组、模型组、清益护肺方低剂量组、清益护肺方高剂量组和甘草酸组。采用15 Gy全胸辐照构建RP小鼠模型,自造模1 d起连续给药干预2周。评估小鼠肺系数;HE染色法观察肺组织病理损伤并采用Szapiel评分进行量化;ELISA法检测支气管肺泡灌洗液(BALF)中HMGB1、TNF-α、IL-1β、IL-6水平;转录组学筛选肺组织差异表达基因并进行GO与KEGG富集分析;Western blot及免疫组化法检测肺组织HMGB1、TLR4、NF-κB及p-NF-κB蛋白表达。采用15 Gy X线照射人正常肺上皮细胞(BEAS-2B)构建RP细胞模型,并通过转染技术调控HMGB1表达。CCK-8法检测细胞活性;测定乳酸脱氢酶(LDH)释放量;ELISA法检测细胞上清液中炎症因子(TNF-α、IL-1β、IL-6)的表达水平,Western blot及免疫荧光法检测HMGB1/TLR4/NF-κB通路相关蛋白的表达。
    结果 与空白对照组相比,模型组小鼠肺组织肺泡壁增厚、支气管周围炎症细胞浸润明显,肺系数、Szapiel评分及BALF中HMGB1等炎症因子水平显著上升,清益护肺方低、高剂量组与甘草酸组肺系数、Szapiel评分及炎症指标均显著降低,肺泡结构破坏与炎症浸润减轻。转录组学基因富集分析显示,清益护肺方干预后的差异基因显著富集于Toll样受体、NF-κB信号通路。Western blot及免疫组化结果显示清益护肺方可显著降低肺组织HMGB1、p-NF-κB p65/NF-κB p65、TLR4蛋白表达。体外实验中,清益护肺方组细胞活力显著升高、LDH释放下降、炎症因子分泌降低、HMGB1/TLR4/NF-κB通路蛋白水平降低,而过表达HMGB1可逆转清益护肺方的上述保护作用。
    结论 清益护肺方能有效改善RP肺损伤,其作用机制可能与抑制HMGB1/TLR4/NF-κB信号通路的活化,减轻炎症反应有关。

     

    Abstract:
    OBJECTIVE To explore the mechanism of Qingyi Hufei Formula (QHF) in treating radiation-induced pneumonia (RP) based on transcriptomics.
    METHODS SPF mice were randomly divided into blank control group, model group, low-dose QHF group, high-dose QHF group, and glycyrrhizic acid (GA) group. A mouse model of RP was established by whole-chest irradiation with a dose of 15 Gy, and the drug intervention was given continuously for 2 weeks from the first day of modeling. The lung coefficient of mice was evaluated, and the pathological damage of lung tissue was observed by HE staining and quantified by Szapiel score. The levels of HMGB1, TNF-α, IL-1β and IL-6 in bronchoalveolar lavage fluid (BALF) were detected by ELISA. Differentially expressed genes in lung tissues were screened by transcriptomics, and GO and KEGG enrichment analysis were performed. The protein expression of HMGB1, TLR4, NF-κB and p-NF-κB in lung tissue was detected by Western blot and immunohistochemistry. Human bronchial epithelial cells (BEAS-2B) were irradiated with 15Gy X-ray to construct RP cell model, and the expression of HMGB1 was regulated by transfection technology. Cell viability was detected by CCK-8 assay. The release of lactate dehydrogenase (LDH) was measured. The levels of TNF-α, IL-1β, and IL-6 in the supernatant were detected by ELISA. The expression of HMGB1/TLR4/NF-κB pathway related proteins was detected by Western blot and immunofluorescence.
    RESULTS Compared with the control group, the model group had thickening of alveolar wall, obvious infiltration of inflammatory cells around the bronchus, and significant increases in lung coefficient, Szapiel score, and inflammatory factors such as HMGB1 in BALF. The lung coefficient, Szapiel score and inflammatory indexes in the low and high dose Qingyihufei Formula groups and GA group were significantly decreased and the destruction of alveolar structure and inflammatory infiltration were alleviated. Transcriptome gene enrichment analysis showed that the differentially expressed genes in the prognosis of Qingyihufei Formula were significantly enriched in Toll-like receptor and NF-κB signaling pathways. Western blot and immunohistochemistry results demonstrated that QHF could significantly reduce the protein expression of HMGB1, p-Nf-κB p65/NF-κB p65 and TLR4 in lung tissue. In the in vitro experiments, QHF significantly increased the cell viability, decreased the release of LDH, decreased the secretion of inflammatory factors, and inhibited the protein expression of HMGB1/TLR4/NF-κB pathway. However, overexpression of HMGB1 reversed the above protective effects of Qingyihufei Formula.
    CONCLUSION Qingyihufei Formula can effectively treat RP possibly by inhibiting the activation of HMGB1/TLR4/NF-κB signaling pathway and reducing inflammatory response.

     

/

返回文章
返回